	Application No.	Applicant(s)	
		DEDIEU ET AL.	
Notice of Allowability	09/654,223 Examiner	Art Unit	
House of Allowanning		1633	
	Dave T Nguyen	1632	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.			
1. This communication is responsive to <u>May 28, 2004</u> .			
2. The allowed claim(s) is/are <u>1-21 and 23-25</u> .			
3. \boxtimes The drawings filed on <u>31 August 2000</u> are accepted by the	Examiner.		
 4. Acknowledgment is made of a claim for foreign priority uses a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have 1. International Bureau (PCT Rule 17.2(a)). 	e been received. e been received in Applicati	on No. <u>08/646,246</u> .	ne
* Certified copies not received:			
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.			
6. ☐ CORRECTED DRAWINGS (as "replacement sheets") mu			
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached			
1) ☐ hereto or 2) ☐ to Paper No./Mail Date			
(b) ☐ including changes required by the attached Examiner Paper No./Mail Date			
Identifying indicia such as the application number (see 37 CFR each sheet. Replacement sheet(s) should be labeled as such in	1.84(c)) should be written on the header according to 37 C	the drawings in the front (not the back) of FR 1.121(d).	
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.			
Attachment(s) 1. Notice of References Cited (PTO-892) 2. Notice of Draftperson's Patent Drawing Review (PTO-948) 3. Information Disclosure Statements (PTO-1449 or PTO/SB Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material) 6. ☐ Interview Paper No 5/08), 7. ☒ Examiner	nformal Patent Application (PTO-152) Summary (PTO-413), J./Mail Date S Amendment/Comment S Statement of Reasons for Allowance	

Page 2

Application/Control Number: 09/654,223

Art Unit: 1632

Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

This examiner's amendment is mainly to correct the informality associated with an entry of a claim amendment. The format for entering a claim amendment, as set forth in the amendment dated 9/8/03, is incorrect, e.g., claims 6, 9, 12, and 20. The previous examiner's amendment does not address this informality. Thus, the following examiner 's amendment is to correct the informality.

Claims 6, 9, 12, and 20 have been amended as indicated below.

- 6. (Currently Amended) [An] <u>The</u> adenovirus according to claim [1] <u>2</u>, wherein the heterologous DNA sequence comprises a gene which encodes a product toxic in a cell infected by said adenovirus.
- 9. (Currently Amended) [An] <u>The</u> adenovirus according to claim [1] <u>2</u>, wherein the heterologous DNA sequence comprises a gene which encodes a product effective to inhibit cell division.

Application/Control Number: 09/654,223

Art Unit: 1632

12. (Currently Amended) A composition comprising [a] the replication defective recombinant adenovirus according to claim [1] 2 and an acceptable carrier.

20. The adenovirus of claim 2, wherein the expression signal comprises a promoter sequence from an Epstein-Barr virus.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner *Dave Nguyen* whose telephone number is **571-272-0731**.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, *Amy Nelson*, may be reached at **571-272-0804**.

Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center number, which is **703-872-9306**.

Any inquiry of a general nature or relating to the status of this application should be directed to the *Group receptionist* whose telephone number is **(703) 308-0196**.

DAVET, NGUYEN PRIMARY EXAMINER

Dave Nguyen
Primary Examiner
Art Unit: 1632